204.74 -0.36 (-0.18%)
After hours: 4:10PM EDT
|Bid||205.15 x 800|
|Ask||205.13 x 800|
|Day's Range||203.03 - 205.25|
|52 Week Range||163.31 - 205.25|
|PE Ratio (TTM)||61.44|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||5.28 (2.63%)|
|1y Target Est||204.05|
Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
THOUSAND OAKS, Calif. and LOS ANGELES, Sept. 20, 2018 /PRNewswire/ -- Amgen (AMGN) and the County of Los Angeles today announced that Amgen has agreed to become a founding sponsor of BioLA, a newly formed organization focused on advancing a life science innovation hub in Los Angeles County. The innovation hub is designed to contribute to advancements in global health by strengthening the County's life sciences ecosystem and accelerating the pace of startup activity.
AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.
On Monday, GuruFocus' High Quality Screener listed three biotechnology companies that offer good potential ahead of the fourth quarter: Biogen Inc. (BIIB), Gilead Sciences Inc. (GILD) and Novo Nordisk A/S (NVO). Warning! GuruFocus has detected 4 Warning Signs with ORCL. Berkshire Hathaway Inc. (BRK-A)(BRK-B) CEO Warren Buffett (Trades, Portfolio) has stressed several times that key investing criteria include predictable earnings and strong economic moat.
THOUSAND OAKS, Calif., Sept. 17, 2018 /PRNewswire/ -- Amgen (AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), today announced results from the largest global survey to date investigating perceptions of Alzheimer's disease. Findings show that most adults (62 percent) are worried they may develop Alzheimer's, while nearly the same proportion believe it is likely a cure will be developed in their lifetime (60 percent).1 This World Alzheimer's Month, Amgen, Novartis, BAI and ADI are raising awareness about how volunteers can take part in clinical studies to benefit Alzheimer's research, potentially themselves and future generations.
On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.
On September 14, Teva Pharmaceutical Industries (TEVA) announced that the FDA had approved fremanezumab, its long-awaited migraine drug. The FDA had delayed the approval for the drug, which had been expected in June, due to a warning letter to Teva’s manufacturing partner Celltrion. The FDA provided a PDUFA (Prescription Drug User Fee Act) date of September 16.
American depository receipts jumped in morning trading on Monday, Sept. 17, following the news late Friday that the company had clinched the U.S. Food and Drug Administration's nod for its migraine drug. It is the second anti-calcitonin gene-related peptide (CGRP) drug approved by the agency to prevent migraines, after Amgen Inc. CGRP is thought to play a key role in causing migraine headaches.
Teva Pharmaceutical Industries Ltd. shares surged nearly 7% in Monday premarket trade after the company's migraine therapy, intended to prevent chronic attacks of head pain along with other severe, disabling symptoms, was approved by the U.S. Food and Drug Administration. The therapy, Ajovy, is administered as an injection, using a prefilled syringe, and can be dosed on a quarterly or monthly basis. The monthly dose will cost $575 per dose and the quarterly dose will cost $1,725, Teva said, meaning the product's total yearly cost will be about $6,900 per year irrespective of dose. The pricing figures released by Teva refer to the therapy's wholesale acquisition cost, or the price a drugmaker offers wholesalers, from which discounts are typically taken. About 38 million Americans, or 12% of the population, experience migraines, and though the treatment landscape has been sparse so far, it is poised to become increasingly competitive. Another preventative therapy, from Amgen Inc. and Novartis AG [S: nvs] was approved by the FDA in May, and the companies cited the same price tag, or $6,900. A FDA decision for another drug in this class, from Eli Lilly & Co. , is expected in the near future as well. For the beleaguered Teva, the new approval is a "clear positive," said J.P. Morgan analyst Chris Schott, though he noted "the highly competitive dynamics in the space with Amgen, Teva and Lilly all launching within six months of each other and with relatively limited differentiation among agents." Schott expects Teva's migraine therapy could sell about $150 million next year and as much as $600 million by 2022; even so, he sees "few growth drivers or pipeline assets beyond Ajovy" given generic competition for the company's flagship multiple sclerosis medication and challenging conditions for generic drugs. Shares of the U.S.-listed Teva have surged 20.6% year-to-date, while the S&P 500 has risen 8.7% and the Dow Jones Industrial Average has lifted 5.8%.
Teva Pharmaceutical Industries Ltd. climbed as much as 7.4 percent in early U.S. trading after FDA approval of its migraine drug, Ajovy, surprised the Street. The medicine is the second of its kind, behind Amgen’s Aimovig, and has the potential to reach sales of $1 billion in four years, according to BTIG analyst Timothy Chiang. “Teva continues to move in the right direction, now run by strong management, which is implementing deep cost reductions.
Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.
This big biotech might look more like a big pharma with sluggish growth but great dividends -- at least temporarily.
AstraZeneca’s (NYSE:AZN) profits look poised to resume growing, as a number of the drug company’s new treatments are expected to be approved by regulators. While ultimately the new drugs should compensate for the lost Crestor sales, it’s too early to say when the positive outlook will be reflected in AZN stock. If these forecasts hold, and AZN stock can trade consistently above $40 per share, AstraZeneca stock could finally rally.
THOUSAND OAKS, Calif. , Sept. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9 a.m. GMT on Friday, Sept. 14, 2018 , in London ...
Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting.
The Dow Jones Industrial Average declined 0.23 percent to close at 25,857.07, while the S&P 500 Index increased 0.19 percent to close at 2,877.13. The Nasdaq Composite Index gained 0.27 percent to close at 7,924.16. Amgen's stock jumped 3.16% Monday, to close the day at $202.50.